COST-EFFECTIVENESS OF CANNABIDIOL (CBD) FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TREATMENT-RESISTANT LENNOX-GASTAUT SYNDROME OR DRAVET SYNDROME IN THE NETHERLANDS

被引：0
|
作者：
Siddiqui, J. [1 ]
Bowditch, S. [2 ]
机构：
[1] FIECON Ltd, London, England
[2] Jazz Pharmaceut, London, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE400
引用
收藏
页码：S127 / S128
页数：2
相关论文
共 50 条
  • [21] Clinically meaningful reduction in drop seizures in patients with Lennox-Gastaut syndrome treated with cannabidiol (CBD)
    Specchio, N.
    Auvin, S.
    Greco, T.
    Lagae, L.
    Nortvedt, C.
    Zuberi, S.
    ANNALS OF NEUROLOGY, 2025, 96 : S51 - S51
  • [22] The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK
    Benedict, Agnes
    Verdian, Lara
    Maclaine, Grant
    PHARMACOECONOMICS, 2010, 28 (03) : 185 - 199
  • [23] Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
    Devinsky, Orrin
    Patel, Anup D.
    Cross, J. Helen
    Villanueva, Vicente
    Wirrell, Elaine C.
    Privitera, Michael
    Greenwood, Sam M.
    Roberts, Claire
    Checketts, Daniel
    VanLandingham, Kevan E.
    Zuberi, Sameer M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (20): : 1888 - 1897
  • [24] Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain
    Garcia-Penas, Juan J.
    Nagel-Rein, Antonio Gil
    Sanchez-Carpintero, Rocio
    Villanueva-Haba, Vicente
    REVISTA DE NEUROLOGIA, 2021, 73 : S1 - S8
  • [25] Exposure-Response Analysis of Cannabidiol (CBD) Oral Solution for the Treatment of Lennox-Gastaut Syndrome
    Morrison, Gilmour
    Sardu, Maria Luisa
    Rasmussen, Christian Hove
    Sommerville, Kenneth
    Roberts, Claire
    Blakey, Graham E.
    NEUROLOGY, 2018, 90
  • [26] Treatment of Lennox-Gastaut syndrome
    Hancock, Eleanor C.
    Cross, J. Helen
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02):
  • [27] Treatment of Lennox-Gastaut syndrome
    Hancock, E. C.
    Cross, H. H. J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03):
  • [28] Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK
    Á Benedict
    L Verdian
    G Maclaine
    PharmacoEconomics, 2011, 29 : 1014 - 1014
  • [29] Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Wijnen, Ben
    Armstrong, Nigel
    Ramaekers, Bram
    Witlox, Willem
    Westwood, Marie
    Fayter, Debra
    Ryder, Steve
    Buksnys, Titas
    Worthy, Gill
    Misso, Kate
    Grimm, Sabine
    Kleijnen, Jos
    Joore, Manuela
    PHARMACOECONOMICS, 2020, 38 (10) : 1043 - 1053
  • [30] Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome
    Nabbout, Rima
    Arzimanoglou, Alexis
    Auvin, Stephane
    Berquin, Patrick
    Desurkar, Archana
    Fuller, Douglas
    Nortvedt, Charlotte
    Pulitano, Patrizia
    Rosati, Anna
    Soto, Victor
    Villanueva, Vicente
    Cross, J. Helen
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2023, 110 : 78 - 85
12345